CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Operating expenses:
Research and development	$ 79,490	$ 177,087	$ 142,951	$ 247,183
General and administrative	14,521	20,023	28,842	39,700
Total operating expenses	94,011	197,110	171,793	286,883
Loss from operations	(94,011)	(197,110)	(171,793)	(286,883)
Other income (expense):
Other income (expense), net	5,842	(67)	14,071	(71)
Total other income (expense), net	5,842	(67)	14,071	(71)
Loss before provision for income taxes	(88,169)	(197,177)	(157,722)	(286,954)
Provision for income taxes	2,177	6,110	3,116	13,365
Net loss	$ (90,346)	$ (203,287)	$ (160,838)	$ (300,319)
Net loss per share attributable to common shareholders of Biohaven Ltd. — basic (in dollars per share)	$ (1.32)	$ (5.16)	$ (2.36)	$ (7.63)
Net loss per share attributable to common shareholders of Biohaven Ltd. — diluted (in dollars per share)	$ (1.32)	$ (5.16)	$ (2.36)	$ (7.63)
Common shares outstanding—basic (shares)	68,248,023	39,375,944	68,227,564	39,375,944
Common shares outstanding—diluted (shares)	68,248,023	39,375,944	68,227,564	39,375,944
Net loss	$ (90,346)	$ (203,287)	$ (160,838)	$ (300,319)
Other comprehensive loss, net of tax	(146)	0	(264)	0
Comprehensive loss	$ (90,492)	$ (203,287)	$ (161,102)	$ (300,319)